IWP Capital Supports FedEx's Call for a Risk Report on Abortion-Drug Distribution

IWP Capital Backs FedEx Proposal 6 on Abortion Drug Distribution Risks

In an important move regarding the distribution of abortion drugs, IWP Capital, LLC, a faith-based investment firm, announced its intention to support Proposal 6 during the FedEx Corporation's 2026 annual meeting. This proposal seeks to address the potential risks that FedEx may encounter when transporting mail-order abortion drugs, notably mifepristone.

Scheduled to be voted on at the shareholder meeting on September 28, 2026, the proposal does not request FedEx to cease shipping any lawful products or to inspect packages. Instead, it insists that FedEx's board provide a comprehensive report addressing the legal, regulatory, and reputational risks associated with the distribution of these drugs within one year and at a reasonable cost. This initiative was co-filed by IWP Capital in collaboration with the Catholic Diocese of Fort Worth.

Sam Saladino, CEO of IWP Capital, emphasized the necessity for transparency in managing risks linked to the distribution of abortion drugs amid uncertainties regarding the enforcement of the Comstock Act. Saladino articulated that the stakes are high; the legal ambiguity surrounding the shipment of such products constitutes a considerable risk that shareholders deserve to be informed about. He stated, “We are asking a board that emphasizes risk oversight to tell its owners how it is preparing for a criminal statute whose enforcement is genuinely unsettled.”

This proposal recognizes the dual pressures that FedEx faces: on one side, there is pressure from investors that advocate for continuous access to abortion drugs, while concurrently, faith-based groups may insist on the company’s adherence to certain ethical guidelines. These competing interests underline the importance of having a thorough governance framework in place. IWP Capital encourages fellow shareholders to carefully scrutinize the proposal and consider lending their support as well, given its procedural and precatory nature.

Furthermore, it’s crucial to note that this public statement from IWP Capital is an indication of its voting preference regarding Proposal 6. They clarify that they are not soliciting proxy authority to vote on behalf of other shareholders but encourage individuals to utilize FedEx's official proxy materials to cast their votes.

As the September 28 meeting approaches, the focus on ethical investment practices and corporate governance strategies remains a hot topic among FedEx shareholders and stakeholders alike. The implications of this proposal could potentially ripple through the larger discourse of corporate responsibility, shareholder activism, and ethical compliance in the fast-evolving landscape of the pharmaceutical and logistics industries.

IWP Capital's advocacy for this board-level review reflects a growing trend among investors who are becoming more attuned to the implications of corporate accountability, especially in sensitive sectors. The outcome of the vote will not only have ramifications for FedEx's operational approach but also set a precedent for how companies address moral dilemmas intertwined with legal obligations. As stakeholders await the results, the conversation surrounding the transportation of abortion drugs is likely to intensify, marking a critical moment for FedEx and its shareholders.